RJA
NAUT icon

Raymond James & Associates’s Nautilus Biotechnolgy NAUT Stock Holding History

Raymond James & Associates’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-18,797
Closed -$115K – 4237
2021
Q3 		$115K Buy
18,797
+2,863
+18% +$22.8K ﹤0.01% 3806
2021
Q2 		$161K Buy
15,934
+4,394
+38% +$47.6K ﹤0.01% 3740
2021
Q1 		$159K Buy
+11,540
New +$160K ﹤0.01% 3677

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
AEPBI
AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Raymond James & Associates's NAUT Position: Q4 2021 in Review

Raymond James & Associates sold out of Nautilus Biotechnolgy (NAUT) in Q4 2021, closing a stake of 18,797 shares — an estimated $115K sold.

Raymond James & Associates first reported a position in NAUT in Q1 2021 and held it in 3 quarters. The position peaked at $161K in Q2 2021. 81 funds tracked by Wall St. Rank hold NAUT as of Q4 2021.

  • Raymond James & Associates reported no remaining Nautilus Biotechnolgy position as of Q4 2021 after selling out during the quarter.
  • Raymond James & Associates sold 18,797 Nautilus Biotechnolgy shares in Q4 2021, an estimated $115K.
  • Raymond James & Associates first reported a position in Nautilus Biotechnolgy in Q1 2021 and held it in 3 quarters.
  • Raymond James & Associates's Nautilus Biotechnolgy position peaked at $161K in Q2 2021.
  • 81 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.